

# Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

NCT06365619

---

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Utah
Enrollment	25 participants

## Plain Language Summary

---

This study is testing whether two immunotherapy drugs — ipilimumab and nivolumab — given before surgery can improve outcomes for people with melanoma (skin cancer) that has come back and can potentially be removed surgically.

**\*\*You may be eligible if...\*\***

- You are 18 or older
- You have been diagnosed with advanced melanoma (Stage IIIB–D or Stage IV) that has returned and is considered removable by a surgeon
- Your recurrence was confirmed by a biopsy while receiving a specific type of immunotherapy (anti-PD-1 therapy)
- You have acceptable organ function and performance status

**\*\*You may NOT be eligible if...\*\***

- Your melanoma is in the eye (uveal melanoma) or originated in a mucous membrane
- You have active autoimmune disease requiring treatment
- You have received certain prior treatments that would conflict with the study drugs
- You are pregnant or breastfeeding

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (26)

- Subjects aged e 18 years.
- Histologically confirmed Stage IIIB-D or Stage IV recurrent metastatic melanoma that is resectable or borderline resectable as determined by a Surgical Oncologist.
- Recurrent disease at eligibility must have been confirmed with biopsy while receiving or within 3 months of completion of adjuvant anti-PD1 therapy.
- ECOG Performance Status d 1.
- Adequate organ function as defined as:  
... and 21 more (see full listing online)

### Exclusion (24)

- Receiving other investigational agents currently or within 28 days of study treatment.
- Prior systemic anti-cancer therapy d 14 days or within five half-lives prior to starting study treatment, whichever is shorter.
- Prior radiotherapy 45 days prior to the first dose of study treatment.
- Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.
- Active infection requiring the use of systemic antibiotics

... and 19 more (see full listing online)  
<https://clinicaltrials.gov/study/NCT06365619>

## Locations (1 total)

---

Huntsman Cancer Institute, Salt Lake City, Utah, United States

---

<https://clinicaltrials.gov/study/NCT06365619>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).